BioMarin Pharma (BMRN) Posts Q4 Loss of $0.03/Share
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $63.81 +3.82%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
BMNM, KG, NHC, More
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
BMNM, KG, NHC, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 GAAP EPS of ($0.03), which may not compare to the analyst estimate of ($0.24). Revenue for the quarter came in at $353.2 million versus the consensus estimate of $377.35 million.
GUIDANCE:
BioMarin Pharma sees FY2019 revenue of $1.68-1.75 billion, versus the consensus of $1.73 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- Evommune, Inc. (EVMN) Misses Q2 EPS by 20c
- Atossa Genetics (ATOS) Tops Q2 EPS by 10c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
